Rituximab + Placebo
Phase 2/3Completed 0 watching 0 views this week📈 Rising
65
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Childhood Idiopathic Nephrotic Syndrome
Conditions
Childhood Idiopathic Nephrotic Syndrome
Trial Timeline
Dec 1, 2010 → May 1, 2014
NCT ID
NCT01268033About Rituximab + Placebo
Rituximab + Placebo is a phase 2/3 stage product being developed by Roche for Childhood Idiopathic Nephrotic Syndrome. The current trial status is completed. This product is registered under clinical trial identifier NCT01268033. Target conditions include Childhood Idiopathic Nephrotic Syndrome.
Hype Score Breakdown
Clinical
22
Activity
15
Company
10
Novelty
7
Community
8
Clinical Trials (3)
| NCT ID | Phase | Status |
|---|---|---|
| NCT02433522 | Phase 3 | Completed |
| NCT01268033 | Phase 2/3 | Completed |
| NCT00372892 | Phase 2 | Completed |
Competing Products
20 competing products in Childhood Idiopathic Nephrotic Syndrome